trending Market Intelligence /marketintelligence/en/news-insights/trending/9Cxxjpwj4PItD3YqvikjqA2 content esgSubNav
In This List

XBiotech starts tender offer to buy up to $420M of its common shares

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


XBiotech starts tender offer to buy up to $420M of its common shares

XBiotech Inc. started a tender offer to buy up to $420 million of its common shares at a price of between $30 and $33 apiece.

The Austin, Texas-based biopharmaceutical company said the offer will provide the company's shareholders the opportunity to obtain liquidity with respect to all or a portion of their stock in the company without disrupting XBiotech's stock price.

The offer is subject to certain terms and conditions. The tender offer will expire at 5 p.m., New York City time on Feb. 12 unless the offer is extended.

D.F. King & Co. Inc. will be information agent for the tender offer.

XBiotech develops therapies based on harnessing naturally occurring antibodies from patients with immunity to various diseases.

In December 2019, Johnson & Johnson acquired all rights to XBiotech's experimental anti-inflammatory antibody bermekimab in a $750 million deal. XBiotech was developing bermekimab as a potential treatment for different cancer types; diabetes; cardiovascular diseases; and skin disorders, including atopic dermatitis, or eczema, and hidradenitis suppurativa.